Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 3/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 11/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 11/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008217 | 0.89 | PPARG (0.45) | CYSLTR2CYSLTR1ERN1 | |
| SCHEMBL2007273 | 0.85 | SLC9A1 (0.33) | FFAR4NR3C1PGRNR3C2AR | |
| SCHEMBL4973300 | 0.84 | CYSLTR2 (0.38) | CYSLTR2CYSLTR1ERN1 | |
| SCHEMBL2006644 | 0.77 | KDM4E (0.34) | ERN1SLC9A1 | |
| SCHEMBL4973294 | 0.77 | ERN1 (0.35) | ERN1SLC9A1 | |
| SCHEMBL10978263 | 0.73 | LTB4R (0.47) | LTB4RLTB4R2CTSDCYSLTR2CYSLTR1 | |
| SCHEMBL9754040 | 0.73 | CYSLTR2 (0.45) | LTB4RLTB4R2CTSDCYSLTR2CYSLTR1 | |
| SCHEMBL7046976 | 0.73 | CYSLTR2 (0.45) | LTB4RLTB4R2CTSDCYSLTR2CYSLTR1 | |
| SCHEMBL10455677 | 0.72 | CYSLTR2 (0.37) | LTB4RLTB4R2CTSDCYSLTR2CYSLTR1 | |
| SCHEMBL1020142 | 0.70 | SMN1; SMN2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| EP-1965785-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. Organon (NL) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | LTB4R 380/4885LTB4R2 460/4885CTSD 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.